:strip_icc()/s.glbimg.com/jo/g1/f/original/2017/07/20/mutacaohiv_SCJKqFW.jpg)
[ad_1]
A team of Israeli researchers evaluated the response of a new vaccine in human patients and tested on monkeys found in five countries: Rwanda, South Africa, Thailand, Uganda and the United States. In the case of volunteer patients, the application has led to "robust immune responses" against the virus. The results were published in the magazines "The Lancet".
The vaccine is a "mosaic". It is a patchwork of genetic sequences found in different strains of HIV. In the case of humans, the team led by researcher Dan H. Barouch applied a standard dose to 393 people in good health – the idea was to test the safety, tolerance and ability to trigger immune responses.
"This study demonstrates that this mosaic vaccine candidate induces robust and comparable immune responses in humans and monkeys," said Barouch, who is also a professor at Harvard Medical School.
The same vaccine was tested on rehsus monkeys. They were infected after using the vaccine, and they had 67% protection against HIV. According to experts, this is the 5th idea of a vaccine that is tested for efficacy in humans in the 35-year history of the virus. More conclusive results should be presented in 2021 or 2022, write the authors.
In early June, the journal Nature Medicine brought another experimental HIV vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) in the United States to neutralize dozens of strains of virus .
Based on the structure of a site vulnerable to HIV, the vaccine induced antibody production in mice, guinea pigs and monkeys, which neutralized dozens of HIV strains of the world whole.
A preliminary human study is expected to begin in the second half of 2019.
Source link
